Tiago Cordeiro Felismino: Exploring the Role of Neutrophil-to-Lymphocyte Ratio in Advanced HCC Treatment
Tiago Cordeiro Felismino, Chief at A.C.Camargo Cancer Center, shared a post on LinkedIn:
“Liver tumors, particularly hepatocellular carcinoma (HCC), are on the rise in Western countries, largely due to metabolic liver diseases.
The advent of immunotherapy has revolutionized advanced HCC treatment, significantly improving response rates and survival.
Still, about 20–40% of patients do not benefit, and to date, there are no validated biomarkers to identify this group.
Interestingly, a simple test — the complete blood count — may provide a clue. The Neutrophil-to-Lymphocyte Ratio (NLR) can help identify patients less likely to respond to immunotherapy.
Our group has recently shown this in a published study.”
Title: Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Biomarker in Advanced Hepatocellular Carcinoma Treated with First-Line Immunotherapy
Authors: Tiago Felismino, Luanna Martins, Matheus Barroso, Daniela Carvalho, Angelo Brito, Claudia Maccali, Felipe Coimbra
Read the Full Article.
More posts on hepatocellular carcinoma.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023